Lawrence Klein

Director at Dyne Therapeutics

Dr. Klein is currently chief business officer at CRISPR Therapeutics, where he previously served as vice president of strategy and corporate development. Before joining CRISPR, he was an associate partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotech companies on a wide range of topics, from strategy to operations. He received his B.S. in biochemistry and physics from the University of Wisconsin-Madison and his Ph.D. in biophysics from Stanford University.
By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.